I Know First Review: September 28th, 2016

I Know First Review

In this post for I Know First Review, the stocks selected here are the top performing stocks from I Know First: Daily Market Forecast’s August 28th, 2016 stock forecast titled, Biotech Stocks to Buy Based on Predictive Statistics: 132% In 30 Days.

This forecast is part of the “Biotech Stocks” package, as one of I Know First’s quantitative investment solutions. The “I Know First Average” return was 20.53% in 1 month, against the S&P 500’s return of 0.11% over the same time period.

I Know First Review

Learn how to read the predictions: Instructions

Learn how to strategize with the forecast: Algorithmic Trading Strategies 

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Signal: 58.89

Predictability: 0.25

Return: -13.66%

StemCells, Inc (STEM)a biopharmaceutical company, is currently engaged in clinical development of its proprietary HuCNS-SC (purified human neural stem cells) platform technology to treat diseases of the human central nervous system (CNS).  The stock decreased by 13.66%.  The decrease is attributed to the volatility as a nano-cap stock, losing hype after its strategic merger with Microbot Medical Ltd. in August 16, 2016, and S&P Equity Research lowering its price target from $1.57 to $1.31.

Signal: 54.43

Predictability: 0.27

Return: 1.36%

Medivation Inc (MDVN), a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers Xtandi for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients.  The stock saw an increase of 1.36% during the 1  month period.  After entering an agreement with Pfizer to be sold for $14 billion on Aug. 22, 2016, the stock increased by 19.73 on that day.  Since then the stock has risen to settle closer to Pfizer’s agreed upon price per share purchase of $81.50.

Signal: 41.48

Predictability: 0.21

Return: 9.30%

Bovie Medical Corporation (BVX) is an energy-based medical device company. It designs, develops, and manufactures electrosurgical equipment used in doctor’s offices, surgery centers, and hospitals worldwide.  The I Know First algorithm had correctly predicted the stock return of 9.30%. This increase was due not only to favorable second quarter earnings, posting consistent revenue increase, but also an increase in insider trading in a positive sentiment, increase in shares being bought. JMP Securities reiterated their “outperform” rating on Sept. 22, 2016.

Screen Shot 2016-08-29 at 2.53.13 PM

Signal: 24.13

Predictability: 0.17

Return: 0.00%

Sequenom, Inc. (SQNM) is a life sciences company, engages in the provision of early patient management information. It develops and commercializes molecular diagnostic testing services that serve women’s health and oncology markets, both US markets and international ones as well. In a span of 1 month, the stock price resulted unchanged with a 0.00% return.  The unchanged price return can be a result of the completion of Labcorp acquisition of Sequenom in a $371 million deal on September 7, 2016.

Signal: 16.44

Predictability: 0.33

Return: 23.25%

Raptor Pharmaceutical Corp. (RPTP), is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. I Know First’s algorithm correctly predicted an increase of 23.25%.  The reason for its increase was Horizon Pharmaceutical’s agreement to acquire Raptor Pharmaceutical Corp. in a $800 million deal on September 12, 2016.

Signal: 14.33

Predictability: 0.24

Return: 10.89%

Insmed, Inc. (INSM) designs, manufactures, and sells electronic data storage products in the Asia Pacific, the Americas, and EMEA countries. The company is based out of Dublin, Ireland.  The stock decreased by 2.48% in a year period. Although Seagate has recovered most of its losses in part due to encouraging second quarter earnings, however the company is facing a decrease in market demand for PCs.

Signal: 13.08

Predictability: 0.20

Return: 132.41%


Sarepta Therapeutics Inc. (SRPT), a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic. The I Know First algorithm accurately predicted a positive return of 134.41%. The positive return was as a result of a licensing deal with Summit Therapeutics (SMMT). Sarepta acquired the rights to Summit’s Duchenne Muscular Dystrophy pipeline which includes the ezutromid therapy. This deal makes Sarepta more attractive for mergers and acquisitions. Although the drug may not be entirely effective, Sarepta’s move on their competitor for a small price of $40 million upfront and $522 million dependent on certain milestones, will eliminate overhang if the drug succeeds.

Signal: 11.28

Predictability: 0.18

Return: 37.95%


Ariad Pharmaceuticals, Inc. (ARIA), an oncology company, engages in the discovery, development, and commercialization of drugs for cancer patients in the United States and internationally.  The stock price rose 37.95% during the 1 month period, as predicted by I Know First’s algorithm. The increase can be attributed to speculation of a possible takeover. Last year in August, Baxalta Inc., expressed interest in acquiring Ariad, but disagreed in price.

Signal: 11.11

Predictability: 0.37

Return: 4.00%

Regeneron Pharmaceuticals, Inc. (REGN) is a biotech company that focuses on neurotrophic factors and their ability to regenerate, as well as cytokine and tyrosine kinase receptors. Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, NY.  REGN’s stock price increased by 4.00% as indicated by I Know First’s algorithm. This was as a result of favorable analysts ratings from Roth Capital, Citigroup, and Brean Capital. restating a buy rating with a price target of $520, a potential increase of over 30% from its current price.

Signal: 10.10

Predictability: 0.23

Return: -0.20%
BioMarin Pharmaceutical, Inc. (BMRN) is a pharmaceuticals company headquartered in San Rafael, CA.  The company develops and commercializes pharmaceuticals, such as Vimizim and Kuvan, to treat serious diseases.  The stock price decreased by 0.20%. This was as a result of receiving unfavorable decisions from the Patent Trial and Appeals Board against Sarepta Therapeutics, Inc. on September 20, 2016.  This results in Biomarin potentially not receiving royalties from Sarepta, which could alter future revenue.

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article.